Inari is offering 7,333,000 shares of its common stock. In addition, Inari expects to grant the underwriters a 30-day option to purchase up to an additional 1,099,950 shares of its common stock.
The FLARE IDE Study has been published. The study was published in JACC: Cardiovascular Interventions. FLARE was conducted under the direction of co-principal investigators, Dr. Kenneth Rosenfield, Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital, Boston and Dr. Victor Tapson, Associate Director, Pulmonary and Critical Care Division at Cedars-Sinai Medical Center, Los Angeles.
9/27/18: CLOUT is a 500-patient prospective, multicenter, single-arm registry to evaluate real world outcomes after treatment of patients with thrombosis in the deep veins of the lower extremity with ClotTriever.
Inari Medical Announces Completion of Patient Enrollment in the FLARE Study for the Treatment of Pulmonary Embolism- A Milestone!
"Finishing enrollment of FLARE represents another major milestone for Inari Medical," said CEO Bill Hoffman.